As of 2025-09-18, the Relative Valuation of Urogen Pharma Ltd (URGN) is (33.16) USD. This relative valuation is based on P/E multiples. With the latest stock price at 18.10 USD, the upside of Urogen Pharma Ltd based on Relative Valuation is -283.2%.
The range of the Relative Valuation is (14.87) - (50.05) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 4.3x - 14.9x | 9.6x |
| Forward P/E multiples | 4.4x - 16.0x | 10.2x |
| Fair Price | (14.87) - (50.05) | (33.16) |
| Upside | -182.2% - -376.5% | -283.2% |
| Date | P/E |
| 2025-09-16 | -5.39 |
| 2025-09-15 | -5.39 |
| 2025-09-12 | -5.61 |
| 2025-09-11 | -5.75 |
| 2025-09-10 | -5.70 |
| 2025-09-09 | -6.18 |
| 2025-09-08 | -6.39 |
| 2025-09-05 | -5.64 |
| 2025-09-04 | -5.61 |
| 2025-09-03 | -5.78 |
| 2025-09-02 | -5.83 |
| 2025-08-29 | -5.81 |
| 2025-08-28 | -5.74 |
| 2025-08-27 | -5.83 |
| 2025-08-26 | -5.82 |
| 2025-08-25 | -5.52 |
| 2025-08-22 | -5.80 |
| 2025-08-21 | -5.90 |
| 2025-08-20 | -5.76 |
| 2025-08-19 | -5.65 |
| 2025-08-18 | -5.79 |
| 2025-08-15 | -5.88 |
| 2025-08-14 | -5.99 |
| 2025-08-13 | -6.00 |
| 2025-08-12 | -5.73 |
| 2025-08-11 | -5.44 |
| 2025-08-08 | -5.30 |
| 2025-08-07 | -5.55 |
| 2025-08-06 | -5.97 |
| 2025-08-05 | -6.19 |
| 2025-08-04 | -5.93 |
| 2025-08-01 | -5.79 |
| 2025-07-31 | -5.69 |
| 2025-07-30 | -5.74 |
| 2025-07-29 | -5.64 |
| 2025-07-28 | -5.64 |
| 2025-07-25 | -5.66 |
| 2025-07-24 | -5.37 |
| 2025-07-23 | -5.57 |
| 2025-07-22 | -5.06 |
| 2025-07-21 | -4.62 |
| 2025-07-18 | -4.56 |
| 2025-07-17 | -4.60 |
| 2025-07-16 | -4.28 |
| 2025-07-15 | -4.19 |
| 2025-07-14 | -4.33 |
| 2025-07-11 | -4.25 |
| 2025-07-10 | -4.37 |
| 2025-07-09 | -4.12 |
| 2025-07-08 | -4.09 |